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Tumor lysis syndrome (TLS) is characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and secondary hypocalcemia
in patients with a malignancy. When these laboratory abnormalities develop rapidly, clinical complications such as cardiac
arrhythmias, acute renal failure, seizures, or death may occur. TLS is caused by rapid release of intracellular contents by dying
tumor cells, a condition that is expected to be common in hematologic malignancies. However, TLS rarely occurs with solid
tumors, and here we present the second chemotherapy-induced TLS in a patient with advanced gastric adenocarcinoma to be
reported in the literature. We also provide information regarding the total cases of TLS in solid tumors reported from 1977 to
present day. Our methodology involved identifying key articles from existing reviews of the literature and then using search terms
from these citations in MEDLINE to ﬁnd additional publications. We relied on a literature review published in 2003 by Baeksgaard
et al., where they gathered all total 45 cases reported from 1977 to 2003. Then, we looked for new reported cases from 2004 to
presentday.Allreports(casereports,briefreports,letterstoeditor,correspondence,reviews,journals,andshortcommunications)
identiﬁed through these searches were reviewed and included.
1.Introduction
Tumor lysis syndrome is a life-threatening oncologic emer-
gency that occurs when a large amount of malignant
tumor cells breakdown rapidly and release their intracel-
lular contents into the systemic circulation causing elec-
trolyte and metabolic disturbances, such as hyperuricemia,
hyperkalemia,hyperphosphatemia,andhypocalcemia.Renal
insuﬃciency, cardiac arrhythmias, seizures, and death due to
multiorgan failure may be the ﬁnal consequences of these
biochemical derangements [1–8].
Tumor lysis syndrome develops usually after the initi-
ation of chemotherapy but in rare cases may arise spon-
taneously before any antitumor therapy has been initiated
[1, 4–19]( Table 1)( Figure 1). TLS is common in patients
with hematologic malignancies with high growth rates or
a large disease burden, but it is rarely observed in patients
with solid tumors of which to date there are only 100 cases
described in the literature [1–93]( Table 1)( Figure 2).
To the best of our knowledge, the present study case is
the second report describing TLS following chemotherapy
for advanced gastric adenocarcinoma [37]. Also, a review of
the literature regarding TLS in solid tumors is presented and
recommendations for management are discussed.
2.CaseReport
The patient is a 57-year-old Hispanic man with a history of
stage III moderately diﬀerentiated gastric adenocarcinoma
intestinal type, diagnosed in late 2006. He was enrolled in a
clinicaltrialforanewregimenofneoadjuvantchemotherapy
consisting of oxaliplatin (85mg/m2 i.v. over 2 hours on days
1 and 15), docetaxel (25mg/m2 i.v. over 30 minutes on days2 Case Reports in Medicine
Table 1: Reported cases of tumor lysis syndrome in solid tumors (1977–2011).
Tumor type Treatment Outcome of TLS Year
published Reference
S m a l lc e l lc a r c i n o m a
DOXO, CDDP, VP-16, VCR Died 1983 [20]∗
DOXO, CTX, VCR Resolved 1983 [21]∗
CCNU, CTX, MTX Died 1988 [22]∗
CDDP, VP-16 Resolved 1988 [22]†
DOXO, CTX, VCR Resolved 1990 [23]∗
DOXO, IF Resolved 1991 [24]‡
CDDP, VP-16 Resolved 1997 [25]∗
CDDP, VP-16 Resolved 1997 [26]∗
CDDP, VP-16 Died 1999 [27]∗
CDDP, VP-16 Died 2001 [28]∗
TOPO Died 2002 [29]∗
CBCDA, VP-16 Resolved 2005 [30]∗
None Died 2011 [9]∗
Squamous cell carcinoma None Resolved 2009 [10]#
None Died 2009 [11]##
Adenocarcinoma of the lung CPT-11, CDDP Resolved 1998 [31]
None Died 2000 [12]
ZOL Died 2005 [32]
DTX Died 2006 [33]
Mixed small cell and nonsmall cell
tumor of the lung CBCDA, PTX Died 2002 [34]
GI tract
None Died 1997 [13]
SUN Resolved 2007 [35]
IMA Died 2007 [36]
Gastric cancer
None Resolved 2001 [14]
CAP, CDDP Resolved 2008 [37]
OX, LV, FUDR, DTX Resolved 2011 Current case
Colorectal cancer
CPT-11 Died 1996 [38]
CPT-11 Died 2000 [39]
None Resolved 2003 [15]
5-FU, LV, CPT-11 Died 2004 [40]
CE Died 2008 [41]
CPT-11, 5-FU, F, BEV Died 2008 [42]
Hepatoblastoma S Died 1990 [43]
CDDP, VCR, 5-FU Resolved 2010 [44]
Hepatocellular carcinoma
TACE Died 1998 [45]
TACE Resolved 1998 [45]
None Died 2003 [15]
RF Resolved 2005 [46]
TH Died 2006 [47]
TOCE Died 2007 [48]
TACE Resolved 2008 [49]
TACE Resolved 2009 [50]
TACE Resolved 2009 [50]
SOR Died 2009 [51]
SOR Resolved 2010 [52]
SOR Resolved 2010 [53]Case Reports in Medicine 3
Table 1: Continued.
Tumor type Treatment Outcome of TLS Year
published Reference
Renal carcinoma
SUN Resolved 2007 [54]
SUN Resolved 2010 [55]
SUN ?? 2011 [56]
Transitional cell carcinoma GC Died 2007 [57]
Prostate cancer
DTX Died 2004 [58]
CAB Died 2004 [59]
PTX Resolved 2005 [60]
CAB Died 2007 [61]
Breast carcinoma
TX Resolved 1986 [62]
5-FU, DOXO, CTX Died 1987 [63]
CTX, MTX, 5-FU Resolved 1989 [64]
MIT Resolved 1994 [65]
None Died 1995 [16]
PTX Died 1997 [66]
RT Died 2000 [67]
CAP Died 2004 [68]
5-FU, EPR, CTX Resolved 2005 [30]
GC, CDDP Resolved 2005 [30]
Ovarian cancer CBCDA, CTX Resolved 1993 [69]
TOPO Resolved 2005 [70]
Endometrial cancer CBCDA, PTX Died 2010 [71]
Vulvar carcinoma CDDP, 5-FU Resolved 1993 [72]
CDDP, 5-FU Died 1998 [73]
Thymoma CDDP, DOXO, CS Resolved 1997 [74]
S Resolved 2004 [75]
Melanoma
TNF-alpha, mAb Died 1994 [76]
IL-1, IF-alpha, CDDP. VIN,
DTIC Resolved 1999 [77]
CDDP, DTIC, IF-alpha Died 2001 [78]
CS Resolved 2002 [79]
CDDP, VIN, DTIC, IF-alpha,
IL-2 Resolved 2004 [80]
TAI-CDDP Resolved 2009 [81]
CS Died 2009 [82]
Gestational trophoblastic neoplasia VP-16, MTX, DACT, CTX, VCR Resolved 2010 [83]
Germ cell tumor
VIN, BL Resolved 1989 [64]
CDDP, VP-16, BL Resolved 2000 [84]
None Resolved 2001 [17]
None Resolved 2001 [17]
BL, VP-16, CDDP Died 2008 [85]
VP-16, CBCDA Resolved 2008 [85]
VP-16, CBCDA Died 2008 [85]
None Died 2010 [18]
Neuroblastoma
VCR, TN, RT Resolved 1994 [86]
RT Resolved 1994 [86]
VCR, TN, RT Resolved 1994 [86]
CTX, TN Resolved 1994 [86]
CTX, DOXO, VCR Resolved 2003 [87]4 Case Reports in Medicine
Table 1: Continued.
Tumor type Treatment Outcome of TLS Year
published Reference
Medulloblastoma RT Resolved 1984 [88]
CDDP, VP-16 Resolved 2003 [89]
Sarcoma
CTX, ALT Resolved 1993 [90]
CBCDA, EPR, VCR Resolved 1993 [91]
CDDP, A, DTIC Resolved 2009 [92]
None Resolved 2010 [19]
None Resolved 2010 [19]
VCR, ACT-D, CTX Resolved 2011 [93]
Total D: 41; R: 58;
??: 1 100
5-ﬂuoracilo (5-FU), tumor necrosis factor alpha (TNF-alpha), interferon-alpha (IF-alpha), anti-GD3 ganglioside monoclonal antibody (mAb), transarterial
chemoembolization (TACE), transarterial oil chemoembolization (TOCE), autolymphocyte therapy (ALT), combined androgen blockade (CAB),
Doxorubicin (DOXO), cisplatin (CDDP), etoposide (VP-16), vincristine (VCR), cyclophosphamide (CTX), lomustine (CCNU), methotrexate (MTX),
ifosfamide (IF), topotecan (TOPO), carboplatin (CBCDA), paclitaxel (PTX), zoledronic acid (ZOL), vinblastine (VIN), bleomycin (BL), teniposide (TN),
radiotherapy (RT), surgery (S), 5-ﬂuoracilo (5-FU), tamoxifen (TX), mitoxantrone (MIT), capecitabine (CAP), gemcitabine (GC), irinotecan (CPT-11),
docetaxel (DTX), corticosteroids (CS), sunitinib (SUN), imatinib (IMA), cetuximab (CE), folinic acid (F), bevacizumab (BEV), dacarbazine (DTIC),
oxaliplatin (OX), ﬂoxuridine (FUDR), leucovorin (LV), interleukin-1 (IL-1), interleukin-2 (IL-2), transcatheter arterial infusion of cisplatin (TAI-CDDP),
radiofrequency (RF), thalidomide (TH), sorafenib (SOR), adriamycin (A), actinomycin-D (ACT-D), dactinomycin (DACT), epirubicin (EPR), died (D),
resolved (R), inaccessible data (??), small cell carcinoma: lung (∗), colon (†), skin (‡); squamous cell carcinoma: lung (#), maxillary sinus (##); none= TLS
developed spontaneously. References: [9–93].
7%
14%
7%
5%
6%
3%
58%
Etiology of tumor lysis syndrome
Chemotherapy
Radiotherapy
Immunotherapy
Hormonotherapy
TACE
Spontaneous
Others
Figure 1: Etiology of tumor lysis syndrome. TACE: transarte-
rial chemoembolization. Others include surgery, bisphosphonates,
radiofrequency, combination of diﬀerent cancer therapies.
1, 8, 15), ﬂoxuridine (110mg/kg i.v. over 24 hours on days 1,
8, 15), and leucovorin calcium (500mg/m2 i.v. over 24 hours
ondays1,8,15)withtreatmentrepeatedevery4weeks.After
the second course (January 2007), he underwent resective
therapy (partial gastrectomy) followed by 2 more cycles of
the above-mentioned chemotherapy regimen as an adjuvant
therapy.
Five months later, recurrence of the primary tumor was
found in the liver; therefore, the patient was started
on a diﬀerent regimen (paclitaxel 120mg/m2, ﬂoxuridine
150mg/kg, leucovorin 500mg/m2, and cisplatin 100mg/
m2), and liver segmentectomy was performed.
Unfortunately, patient failed regular controls, and by
2011 a CT of the chest and abdomen revealed extensive
metastatic liver nodules which ranged from 3.5cm to sub-
centimeter in size, and metastasis to the sternum were also
found. Consequently, he was again included in the initial
experimental chemotherapy regimen as a ﬁrst line therapy
for his metastatic disease (oxaliplatin, docetaxel, ﬂoxuridine,
and leucovorin).
Sevendaysafterreceivingtheﬁrstchemotherapycycle,he
developed nausea, vomiting, oliguria, generalized weakness,
and was referred to the emergency department by his
oncologist due to abnormal laboratory data (Table 2).
On arrival the patient was alert and appeared in poor
general condition, pale, volume depleted with low blood
pressure(102/63mmHg),tachycardia(102/min),respiratory
rate of 20/min, and body temperature of 36.6◦C. A ﬁrm,
nontender, 2cm below the costal margin of the right
midclavicular line hepatomegaly was appreciated. There was
no peripheral lymphadenopathy, and laboratory ﬁndings are
shown on Table 2.
Urinalysis determined urine pH of 5.0 (4.5–7.5). The
chest radiograph appeared to be normal. An EKG demon-
strated atrial ﬁbrillation with rapid ventricular response, left
anterior fascicular block, and peaked T waves (Figure 3). A
renal ultrasound examination revealed an increased bilateral
cortical echogenicity but no evidence of hydronephrosis.Case Reports in Medicine 5
Table 2: Laboratory values before and after chemotherapy.
Parameters Normal ranges Patient’s baseline Abnormal data for which
patient was referred to ER∗ At ER∗
Leukocytes (/mm3) 4,500–11,000 12,000 6,500 7,400
Hemoglobin (g/dL) 14–18 11 8.6 9.6
Hematocrit (%) 42–52 34 26.9 30
Platelets (/mm3) 150,000–400,000 327,000 39,000 37,000
Glucose (mg/dL) 74–106 86 95 104
Sodium (mEq/L) 135–147 138 130 127
Potassium (mEq/L) 3.5–5 4 8.4 8.7
Phosphorus (mg/dL) 3.0–4.5 — — 13.9
Calcium (mg/dL) 8.4–10.2 8.4 5.4 5.4
Uric acid (mg/dL) 3.0–8.2 4.3 17.8 17.6
BUN (mg/dL) 9–20 18 175 183
Creatinine (mg/dL) 0.8–1.5 1.00 15.4 14.98
Total bilirubin (mg/dL) 0.2–1.3 0.5 0.8 0.7
Alkaline phosphatase (U/L) 38–126 381 235 254
AST/ALT (U/L) 15–46/21–72 48/30 44/53 46/58
eGFR (mL/min) >60 >60 3 3
LDH (U/L) 0–250 9,027 — —
pH 7.35–7.45 — — 7.17
PaCO2 (mmHg) 33–44 — — 28
Bicarbonate (mEq/L) 22–28 — — 10
BUN: blood urea nitrogen; AST: aspartate aminotransferase; ALT: alanine aminotransferase; LDH: lactate dehydrogenase. ∗7 days after chemotherapy.
A diagnosis of chemotherapy-induced TLS with acute
renal failure was made. The patient was given vigorous
volumeexpansion,intravenoussodiumbicarbonate,calcium
gluconate, insulin given together with 50% dextrose, and
allopurinol. His laboratory data did not improve and
hemodialysis was started. The patient underwent a total
of 6 hemodialysis over a course of two weeks and was
discharged 18 days after with normal serum electrolyte
and metabolic parameters. However, his renal function
continued to be impaired with a serum creatinine of
3.86mg/dL, blood urea nitrogen of 23mg/dL, and eGFR of
16.
3. Review of the Literature
TLS is an oncologic emergency characterized by severe
electrolyte and metabolic abnormalities due to a rapid
and massive lysis of malignant cells with the release of
intracellular contents into the bloodstream, overwhelming
the excretory and reutilization capacities of the body, leading
to hyperuricemia, hyperkalemia, hyperphosphatemia, and
secondary hypocalcemia [1–8]. As a consequence, these
biochemical disorders can become clinically relevant and
present as renal insuﬃciency, cardiac arrhythmias, seizures,
and death due to multiorgan failure [1–8]. Cairo and Bishop
published the most complete and often referenced deﬁnition
of TLS in 2004. They classiﬁed TLS into two groups,
separating patients exhibiting only laboratory ﬁndings of
TLS from those with potentially life-threatening clinical
presentations. Cairo and Bishop deﬁnitions of laboratory
and clinical TLS are summarized in Table 3 [1–4, 6, 7].
In the setting of a malignancy with a high prolif-
eration rate, large tumor burden, and/or high sensitivity
to treatment, initiation of anticancer treatment, such as
chemotherapy, radiotherapy, resective surgical procedures,
immunotherapy, hormonotherapy, radiofrequency ablation,
or sometimes glucocorticoid therapy alone may result in
the rapid lysis of tumor cells [1, 5–8]( Table 1)( Figure 1).
In addition, TLS can occur spontaneously from the tumor
necrosis prior the onset of anticancer therapy [1, 4–19]
(Table 1)( Figure 1).
Tumor and host-related factors associated with an
increased risk of TLS in solid tumors are mentioned in
Table 4 [1–8]. The tumor-related risk factors are common
characteristics of hematological malignancies, where TLS is a
well-knownclinicalproblem,especiallyinacutelymphoblas-
tic leukemias and high-grade non-Hodgkin’s lymphomas,
and particularly in Burkitt’s lymphoma [1–7]. However, TLS
can rarely occur in solid tumors that have a high proliferative
rate, large tumor burden, and high sensitivity to cytotoxic
therapy [1, 4, 6].
According to the literature review, there have been 100
reported cases of TLS in patients with solid tumors from the
ﬁrst report in 1977 to 2011 (Table 1)( Figure 2), including
s m a l lc e l lc a r c i n o m a s[ 9, 20–30], squamous cell carcinomas
[10, 11], adenocarcinomas of the lung [12, 31–33], mixed
small cell and nonsmall cell lung carcinoma [34], gas-
trointestinal carcinomas [13–15, 35–42], hepatoblastomas6 Case Reports in Medicine
Table 3: Classiﬁcation of tumor lysis syndrome by Cairo and Bishop.
Laboratory TLS
(LTLS) Uric acid ≥8.0mg/dL Phosphorus ≥4.5mg/dL Potassium ≥6.0mmol/L Calcium ≤7.0mg/dL or
ionized calcium <1.12
Clinical TLS
(CTLS) Acute renal failure Cardiac arrhythmia Seizure Sudden death
References: [1–4, 6, 7].
Table 4: Risk factors for tumor lysis syndrome is solid tumors.
Tumor-related factors Host-related factors
Tumor extension Cell lysis potential Pretreatment laboratory
ﬁndings
(i) Low urinary ﬂow
(ii) Dehydration and/or
inadequate hydration
(iii) Preexisting
nephropathy∗
(iv) Exposure to
nephrotoxins
(v) Hypotension
(vi) Obstructive
uropathy
(i) Large tumor burden
(ii) Bulky tumor (≥10cm)
(iii) Extensive metastasis ∧
(iv) Extrinsic compression of
the genitourinary tract by the
tumor
(i) High proliferative
rate
(ii) High sensitivity to
anticancer therapy
(iii)Type and intensity of
initial anticancer therapy
(using a combination of
multiple
chemotherapists)
(i) Elevated LDH
(ii) Elevated serum
creatinine
(iii) Elevated serum uric
acid
(iv) Elevated serum
phosphate
LDH: lactate dehydrogenase. ∧hepatomegaly, splenomegaly, and nephromegaly due to metastasis. Bone marrow inﬁltration. ∗A patient with preexisting
nephropathy from hypertension, diabetes, gout, or other causes is at greater risk for developing acute kidney injury and TLS. References: [1–8].
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Figure 2: Reported cases of tumor lysis syndrome in solid tumors.
Figure 3: EKG from the patient’s admission showing atrial ﬁbrilla-
tion with rapid ventricular response and peaked T waves.
[43, 44], hepatocellular carcinomas [15, 45–53], renal car-
cinomas [54–56], transitional cell carcinoma [57], prostate
carcinomas [58–61], breast carcinomas [16, 30, 62–68],
ovarian carcinomas [69, 70], endometrial carcinoma [71],
vulva carcinomas [72, 73], thymomas [74, 75], melanomas
[76–82], gestational trophoblastic neoplasia [83], germ cell
tumors [17, 18, 64, 84, 85], neuroblastomas [86, 87],
medulloblastomas [88, 89], and sarcomas [19, 90–93]. Most
cases regarded as TLS in solid tumors were chemotherapy-
induced, even though various other causes were pointed out
for TLS in solid tumors as well [3]( Table 1)( Figure 1). The
dominant factor for developing TLS in solid tumors, which
occurred in all 100 cases, was having a large tumor burden.
Another relevant fact was the presence of metastatic disease
observed in 83% of all cases, of which the liver was the
most aﬀected organ; thus, the remaining 17% presented with
bulky primary tumor.
Other risk factors for developing TLS in solid tumors
included pretreatment increased LDH, renal impairment,
hyperuricemia, and hyperphosphatemia found in 86%
(43/50), 26% (18/69), 42% (21/50), and 14% (6/44) of the
evaluable patients in which speciﬁc results were reported,
respectively.Case Reports in Medicine 7
In 7% of the cases, we found hydronephrosis as a high
risk for developing TLS due to compression of the genitouri-
nary tract by the tumor, being particular hazard neoplasms
such as germ cell tumor, prostate cancer, retroperitoneal
sarcoma, and uterus carcinoma.
Irrespectiveofthecancertype,thereisa20–50%increase
in mortality for undiagnosed or late-diagnosed TLS cases in
solid tumors [8]. This high mortality rate may be due to
the fact that in solid tumors, contrary to what is observed
in hematological malignancies, TLS is usually evident after
a few days within treatment when the patient may have
already left the hospital [3, 8]. Another cause is that in
hematologicalmalignancies,prophylacticmeasuresaremore
oftenimplemented,andawarenessofthesyndromeishigher.
The fatality rate of the 100 cases presenting TLS in solid
tumors was found to be 41%.
SymptomsassociatedwithTLSstronglyrevealelectrolyte
and metabolic irregularities, which are hyperkalemia, hyper-
phosphatemia, secondary hypocalcemia, and hyperuricemia
[1–8]. Hyperkalemia, which takes place within 12 to 24
hoursfromtheantineoplastictreatment’sinitiation,becomes
the earliest and most severe laboratory ﬁnding [3]. The
clinical manifestations for hyperkalemia include lethargy,
weakness, paresthesias, muscle cramps, nausea, vomiting,
and abnormalities in the electrocardiogram, such as peaked
T waves, prolonged PR interval, widened QRS complexes,
ventricular tachycardia, ventricular ﬁbrillation, or asystole
[2–5]. Since the phosphorus concentration is higher in
malignant cells than in normal cells (4:1), accelerated
tumor breakdown usually leads to hyperphosphatemia with
the subsequent secondary hypocalcemia [1, 3–7]. Both
electrolyte disturbances, hyperphosphatemia and hypocal-
cemia, may cause a variety of symptoms, such as nausea,
vomiting, lethargy, muscle cramps, tetany, seizures, cardiac
arrhythmias, and/or acute renal failure [2–6]. Accumulation
of uric acid may increase the urinary uric acid concentration
to a point where precipitation occurs, and acute renal failure
may be the consequence. The widespread use of agents
lowering uric acid production or excretion is responsible
for nephrocalcinosis, becoming a major mechanism of acute
renal failure in TLS [1–3, 6]. However, calcium phosphate
precipitation does not only occur in the kidneys, but also
in other soft tissues such as the heart, where it may induce
cardiac arrhythmias [1–3, 6].
The fact that urine is acidic facilitates uric acid to precip-
itate, thus excessive overproduction and over excretion could
accumulate uric acid in the form of crystal precipitation
in the renal tubules, leading to obstructive uropathy with
acute kidney injury [1, 2, 4, 5, 8, 65]. Uric acid or calcium
phosphate accumulation does not always imply urinary tract
symptoms;however,ﬂankpainduetorenalpelvicorureteral
stone formation may occur [1, 4] .T h eu r i n a l y s i sq u i t eo f t e n
discloses a number of uric acid crystals, amorphous urates,
calcium phosphate crystals, and/or hematuria [1, 4].
The treatment principles for TLS are prevention, early
diagnosis, and proper management of disorders [3]. In
2008, an international expert panel published evidence-
based guidelines, for the prevention and treatment of TLS
depending on the malignancy risk category. According to
this evidence-based guidelines unless tumor and/or host-
related risk factors are associated, solid tumors are consid-
ered low risk (<1%) for developing TLS. Thus, adequate
recommendations for the prevention and management of
TLS in solid tumors are accurate hydration prior to therapy
and a “watch and wait” approach with close monitoring
on looking for the ﬁrst biologic derangements characteriz-
ing TLS (hyperuricemia, hyperphosphatemia, hypocalcemia,
increased creatinine level) without any form of prophylactic
hypouricemic therapy or phosphate binders [1–3, 6, 37].
Once TLS is established, the standard therapy strategy
for treating TLS is based on volume expansion, decreasing
the metabolic abnormalities, and in most cases providing
supportive treatment of renal failure [1, 5, 8].
Administration of ﬂuids is important because it increases
renal blood ﬂow, glomerular ﬁltration, and reduces the uri-
narysupersaturationofuricacid,calcium,andphosphate[2,
4, 5, 7]. Patients should receive 3 l/m2/day (200mL/Kg/day if
≤10kg) and have a urine output ≥100mL/m2/h (3mL/kg/h
if ≤10kg) [2–4, 6]. In the absence of obstructive uropathy
and/or hypovolemia, diuretics may be used to maintain
the adequate urine output [2–4, 6, 7]. The utility of low-
dose dopamine to enhance renal blood ﬂow is not as clear
[3].
Maintaining urine pH above 7 with the aid of acetazo-
lamide and/or sodium bicarbonate for the prevention and/or
treatment of TLS may reduce the precipitation of uric acid
crystals but at the same time may decrease the solubility
of calcium phosphate or xanthine, and in the setting of
acute renal failure, metabolic alkalosis may be an unintended
consequence [1, 3, 4, 6, 7]. Consequently, the use of sodium
bicarbonate should be restricted to those patients with severe
metabolic acidosis [1].
Hyperkalemia may be an acute life-threatening emer-
gency in patients with TLS. In case of hyperkalemia, cardiac
membrane stabilization with 10% calcium gluconate may
not be eﬀective in the setting of severe hyperphosphatemia,
and given an increased risk of calcium phosphate tissue
precipitation, calcium administration is only appropriate
for symptomatic hypocalcemia (arrhythmia, hypotension,
tetany, or muscle cramps) [1, 7]. Consequently, measures
to reduce serum potassium or enhance potassium excretion
should have priority. These include primarily insulin and
beta-2 agonists to shift potassium into cells and volume
expansion and loop diuretics to enhance potassium elimina-
tion. Sodium bicarbonate may be used as a slow continuous
infusion in the face of severe acidosis. Exchange resins may
be administered but should not be relied upon in the setting
of acute hyperkalemia due to their unpredictable eﬃcacy.
For patients with renal failure, dialysis should be initiated as
soon as possible [1–7]. For hyperphosphatemia, phosphate
binders and/or hypertonic dextrose with insulin may be used
[1–7].
Allopurinolisacompetitiveinhibitorofxanthineoxidase
(Figure 4), and it has been successfully prescribed for the
treatment of hyperuricemia. Allopurinol is metabolized
to oxypurinol, which in turn inhibits xanthine oxidase;
therefore, it blocks the metabolic process of xanthine and
hypoxanthine to uric acid, leading to an increase in the8 Case Reports in Medicine
Table 5: Similarities and diﬀerences between chemotherapy-induced TLS in advanced gastric adenocarcinoma reported in 2008 and our
case.
Similarities Diﬀerences
(i) Massive liver metastasis
(ii) Elevated pretreatment
LDH
(iii) Large tumor burden
-Outcome of TLS: resolved
Characteristics 2008 case Actual case
Histology Poorly diﬀerentiated Moderately diﬀerentiated
Tumor extension Primary bulky tumor is present Primary tumor was not
present (previously resected)
Pretreatment laboratory data
Slightly elevated serum uric
acid —
Elevated serum phosphate
Host-related risk factors for
developing TLS —D e h y d r a t i o n
Chemotherapy regimen Capecitabine and cisplatin Oxaliplatin, leucovorin,
ﬂoxuridine, and docetaxel
Onset of TLS after receiving
chemotherapy 3d a y s 7d a y s
Reference: [37].
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Figure 4: Mechanism of action of hypouricemic agents. Hyperuricemia is a consequence of the catabolism of purine nucleic acids to
hypoxanthine and xanthine and then to uric acid via the enzyme xanthine oxidase. Allopurinol is a competitive inhibitor of the enzyme
xanthine oxydase. Rasburicase (exogenous urate oxidase) leads uric acid to a more soluble compound, allantoin.
levels of these two metabolites [1, 3–6]. As a result, patients
with massive TLS who have been prescribed allopurinol may
develop xanthine precipitation leading to acute renal failure
[1,2,4,5,7,65].Thiscanbeavoidedbyreplacingallopurinol
with urate oxidase, which catabolizes uric acid to the more
soluble compound allantoin [1–6]( Figure 4). Urate oxidase
is an enzyme that can be found in many mammals except
humans [1, 3, 4, 6]. The two available commercial forms of
urate oxidase are a nonrecombinant form (uricozyme) and
a recombinant form (rasburicase), which is the preferred
one. Rasburicase has been shown to be more eﬀective than
allopurinol, since it has higher uricolytic eﬀect [1, 3–7], it
does not increase xanthine levels [1, 2, 4, 5, 7], and it reduces
high uric acid levels prior treatment initiation [1–7].
In some patients, despite prophylactic and therapeutic
measures, acute renal failure ensues, and its management
includes careful monitoring of ﬂuid intake and output,
electrolyte balance, hypertension control [4], and renal
dialysis [94]. Indications for renal replacement therapy
include volume overload with pulmonary edema or hyper-
tension that is refractory to therapy, low urine output
(oliguria), persistent or symptomatic hyperkalemia, hyper-
phosphatemia, hypocalcemia, and/or hyperuricemia despite
conservative measures, metabolic acidosis with pH lessCase Reports in Medicine 9
than 7.2 or bicarbonate less than 10mEq/l, rapidly rising
blood urea nitrogen greater than 150mg/dL, and neurologic
symptoms secondary to uremia or electrolyte imbalance [4,
95]. From the above-mentioned criteria, oliguria and other
biochemical disturbances related to TLS have become more
frequent indications for dialysis than hyperuricemia since
the introduction of rasburicase [2, 94]. Both hemodialysis
and hemoﬁltration are aﬀective, while peritoneal dialysis is
not [94, 96]. Dialysis should be continued until proper renal
function is reestablished.
4. Discussion
Our patient with metastatic gastric adenocarcinoma devel-
oped metabolic (hyperkalemia, hyperuricemia, hyperphos-
phatemia, and hypocalcemia) and clinical (cardiac arrhyth-
mia and acute renal failure) derangements 7 days after
instituting chemotherapy, meeting CTLS diagnostic crite-
ria. According to previous reports, there are 2 patients
with advanced gastric adenocarcinomas who developed
TLS documented in the literature (34, 35), although only
one occurred after chemotherapy [37]( Table 5). Therefore,
our case would be the second gastric adenocarcinoma
chemotherapy-induced TLS but the ﬁrst to be reported after
the use of the experimental chemotherapeutic regimen con-
sisting on oxaliplatin, leucovorin, ﬂoxuridine, and docetaxel.
Chemotherapy-related nephrotoxicity was less likely due
tothefactthattheanticanceragentsthepatientwasreceiving
are not considered to be nephrotoxic, except for oxaliplatin
and docetaxel which have less than a 1% probability of
causing renal failure, and it usually occurs with high doses
and after repeated exposures.
Large tumor burden, multiple metastases to liver and
bone, the use of combination chemotherapy drugs, pretreat-
ment elevated LDH, and dehydration were the risk factors
that placed the patient in a high-risk group for developing
TLS [1–8], although his renal function and uric acid levels
were normal before getting anticancer treatment.
Thepurposeforgivingsodiumbicarbonatetothepatient
wastocorrectthemetabolicacidosis,ratherthanalkalinizing
urine.Despiteintensivemedicaltreatment,thepatientdevel-
oped refractory electrolyte imbalances, metabolic acidosis,
uremia, and oliguria. Thus, hemodialysis was performed
with an improvement of the mentioned abnormalities, and
the TLS was resolved. However, his renal function never
returned to baseline, which has been linked to increased
morbidity and mortality.
Even though solid tumors with high sensitivty to therapy
are considered to be at high risk for developing TLS,
we noticed that the syndrome was also present in tumor
types considered as relatively insensitive to therapy such
as melanoma, sarcoma, hepatocellular carcinoma, vulvar
carcinoma, non-small cell lung cancer, and gastric cancer.
According to our observations, the predominant risk factors
to induce TLS in solid tumors are large tumor burden and
liver metastases, rather than tumor sensitivity to therapy
agents.
Liver metastases in solid tumors were found in most TLS
cases, regardless whether patients had liver function abnor-
malities or not [3]. Apparently, liver involvement creates
a risk for the development of TLS in solid malignancies,
possible causes being high purine pools, increased tumor
burden, and/or impaired uric acid metabolism [3].
5. Conclusion
Even though TLS in solid tumors is a rare condition, physi-
cians should be aware of it, especially in therapy-sensitive
large burden tumors with metastatic disease, increased
pretreatment LDH, renal impairment, hyperuricemia, and
hyperphosphatemia, all of which are here documented to be
mayor risk factors for the development of TLS.
If there is a possibility to develop TLS, the metabolic
abnormalities should always be corrected before starting
an anticancer regimen, since prevention is the best way to
reduce its high morbidity and mortality.
In conclusion, TLS in solid tumors requires special atten-
tion for its prevention, early diagnosis, and management due
to its poor clinical course. Physicians should be alert since
improvement in the anticancer treatment may increase the
incidence of TLS in solid tumors.
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